DelveInsight’s “Bronchiolitis Obliterans Syndrome Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Bronchiolitis Obliterans Syndrome , historical and forecasted epidemiology as well as the Bronchiolitis Obliterans Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of Bronchiolitis Obliterans Syndrome Market are:

• A study by Vieira et. al. (2014) titled “Bronchiolitis obliterans in patients undergoing allogeneic hematopoietic SCT”, included 1286 patients transplanted between 1979 and 2009 who survived for 100 days or more. The study diagnosed 53 cases of BO, 35 in men and 28 in women.
• Up to half of lung transplant recipients develop BOS within five years of transplantation.
• The survival rate of patients developing BOS is 20% to 40% lower than in patients without BOS.
• The study by Tomikawa and Rodrigues (2015), titled “Current research on pediatric patients with bronchiolitis obliterans in Brazil” mentioned that post-infectious BOs is prevalent especially in some regions in Asia and the southern cone of South America (the south of Brazil, Uruguay, Argentina, and Chile).

 

Request for free sample Report: https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market

 

Some of Bronchiolitis Obliterans Syndrome Companies are:

• Zambon Pharma
• Incyte Corporation
• Genentech
• Sirolimus
• And Many Others

 

Bronchiolitis obliterans syndrome (BOS) is a form of chronic lung allograft dysfunction that affects a majority of lung transplant recipients and is the primary factor limiting long-term transplant survival. It is characterized by progressive airflow obstruction resulting in acute rejection of the graft, followed by infections, or other coexistent condition.

It is an uncommon respiratory disease characterized by fixed airway obstruction, where the bronchioles in the lung become narrowed or blocked by fibrous tissue. The disease is disabling and can be potentially severe. It may be caused occupationally by accidental, acute, high concentration exposure to industrial gases, such as nitrogen dioxide etc.

Bronchiolitis obliterans can also be associated with rheumatoid arthritis and graft-versus-host disease following a lung or hematopoietic cell transplantation. Exposure to certain food flavoring agents, notably the buttery food flavoring agent diacetyl, with the development of bronchiolitis obliterans. Several other risk factors can also lead to the development of BOS such as exposure to inhaled toxins and gases, including sulfur mustard gas, nitrogen oxides, diacetyl, fly ash, and fiberglass. It is also known to occur after a respiratory viral infection (adenovirus, respiratory syncytial virus), especially in case of children.

 

Request for free sample Report: https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market

 

Some of Bronchiolitis Obliterans Syndrome Drugs are:

• Liposomal Cyclosporine A
• Jakafi
• Esbriet
• mTOR inhibitors/proliferation signal inhibitors
• And Many Others

 

Request for free sample Report: https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Bronchiolitis Obliterans Syndrome

3. Competitive Intelligence Analysis for Bronchiolitis Obliterans Syndrome

4. Bronchiolitis Obliterans Syndrome : Market Overview at a Glance

5. Bronchiolitis Obliterans Syndrome : Disease Background and Overview

6. Patient Journey

7. Bronchiolitis Obliterans Syndrome Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Bronchiolitis Obliterans Syndrome Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Bronchiolitis Obliterans Syndrome : Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Bronchiolitis Obliterans Syndrome

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Request for Detailed TOC: https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/bronchiolitis-obliterans-syndrome-market